Live
FierceBiotechFDA rejects Replimune’s melanoma prospect for second timeEndpoints NewsPlan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushEndpoints NewsBayer pharma executive predicts US-Europe price spreads will narrowBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 9, 2026Endpoints NewsFDA rejects Replimune cancer therapy, saying company didn't resolve trial doubtsBioPharma DiveFDA again spurns Replimune melanoma drugIlluminaWill Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo FinanceBioWorldIn the clinic for April 10, 2026BioWorldOther news to note for April 10, 2026BioWorldRegulatory actions for April 10, 2026Endpoints NewsChina biotech’s CRISPR therapy suggests US drugmakers will face competition
FierceBiotech Apr 10, 2026

FDA rejects Replimune’s melanoma prospect for second time

FDA rejects Replimune’s melanoma prospect for second time

Original
Body unavailable. Use the original source.

Directory

59 All